Umicore Eyes Süd-Chemie's Catalyst Unit

Belgian specialty metals and materials group Umicore is interested in acquiring the catalyst unit of Germany's Süd-Chemie, Belgian business daily De Tijd said on Friday.

The newspaper said no deal had been reached and did not specify whether Umicore was looking to buy all Süd-Chemie or just the catalyst division, although the latter was the ultimate prize.

Umicore, which is one of the world's leading producers of automotive catalysts, said on Thursday, after releasing 2009 results, it would consider possible acquisitions, but did not give details. A spokesman said on Friday the company declined to comment on market speculation.

Munich-based Sü-Chemie has two divisions — adsorbents and catalysts — generating sales of about €1.2 billion. Its catalysts are used to produce hydrogen and in emission control. One Equity Partners LLC, which manages funds for JP Morgan Chase, owns 50.41% of the company.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.